PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.\', \'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.\', \'Public Health England, Salisbury, UK.\', \'The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Daniel.Jenkin@ndm.ox.ac.uk.\', \'Nuffield Department of Medicine, University of Oxford, Oxford, UK.\', \'Clinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.\', \'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Andrew.Pollard@paediatrics.ox.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41591-020-01179-4
?:hasPublicationType
?:journal
  • Nature medicine
is ?:pmid of
?:pmid
?:pmid
  • 33335322
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 17.067
?:rankingScore_hIndex
  • 484
is ?:relation_isRelatedTo_publication of
?:title
  • Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33335322>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33335322>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all